The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the industrialization and translation of extracellular vesicles (EVs) for use in regenerative medicine. EVs are membrane-enclosed carriers of bioactive substances that are used for intercellular communication. This funding opportunity aims to support the development of novel EV-based therapeutic platforms for tissue and organ repair in regenerative medicine. The focus is on the production, manufacturing, and use of native or engineered EVs as therapeutics. The goal is to address challenges in the field and advance the translation of EVs into clinical applications. The funding opportunity is open to small business concerns and offers both Phase I and Phase II grants. The projects should focus on large-scale GMP grade production and manufacturing challenges associated with the use of EVs as therapeutics. The application due dates are June 6th of each year from 2023 to 2025. For more information and to apply, visit the solicitation agency URL: link.